Daniel Winokur, MD
Hematology & Oncology · Worcester, MANPI 1609230580
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,225 of the $7,299 with a category attached, or 99.0%. Novartis accounts for 99.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $4,038 and has fallen 98.2% since, to $74 in 2025.
Across 7 payments — averaging $1042.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Apellis Pharmaceuticals, Inc.$74
Across 14 payments — averaging $23,253 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$284K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
What the payments were for
- Consulting fees$7,22599%
- Food & beverage$741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $7,225 |
| Apellis Pharmaceuticals, Inc. | 2 | $74 |
How this compares
$7,299 in reported general payments places this provider in the 70th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 23 | $398,106 |
| CalquenceAcalabrutinib Maleate | 21 | $316,088 |
| BrukinsaZanubrutinib | 17 | $259,431 |
| ImbruvicaIbrutinib | 13 | $196,187 |
| RetevmoSelpercatinib | 12 | $136,274 |
| SprycelDasatinib | 11 | $105,658 |
| EliquisApixaban | 79 | $55,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,940 |
| OxycontinOxycodone Hcl | 11 | $9,379 |
| Sodium Chloride0.9 % Sodium Chloride | 26 | $2,738 |
| Acyclovir | 70 | $1,424 |
| Dexamethasone | 53 | $817 |
| Hydroxyurea | 41 | $691 |
| Ondansetron Hcl | 52 | $689 |
| Lidocaine | 12 | $661 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Worcester
- Tariq MughalWorcester$292K
- Viola ZhuWorcester$164K
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Stephanie BernsteinWinchester$622K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.